Managed care leaders should vet AI tools before use and recheck them over time, and pharmacists need AI literacy, according to two AMCP Nexus 2026 presenters.
News|Articles|August 1, 2004
Ezetimibe/simvastatin
This novel dyslipidemia therapy features a combination of 2 previously approved drugs: ezetimibe and simvastatin. Ezetimibe exerts its effect by selectively inhibiting intestinal cholesterol and related phytosterol absorption. This mechanism of action is complemented by that of simvastatin, which acts through inhibition of the HMG-CoA reductase enzyme. The ezetimibe/simvastatin combination was approved on July 23, 2004, for the treatment of hypercholesterolemia and mixed hyperlipidemia
Advertisement
Advertisement
Related to this article
AI is speeding up managed care pharmacy work, but two pharmacists say human review remains key when tools affect patients' access to medications.
A review of 16 studies linked presurgical melatonin and zolpidem to less postoperative pain, with over 30% less opioid use in some patients.
Prime Therapeutics' Pat Gleason, Pharm.D., outlined T1D screening gaps for plans and his priorities as incoming AMCP president.
Healthcare affordability has emerged as an issue in the Nov. 3 elections that will determine control of the Senate and the House.
Research presented at AMCP Nexus this week explores barriers to prescriptions for atopic dermatitis.
Adults newly diagnosed with narcolepsy type 1 rack up healthcare costs 5.5 times higher than people without the condition, a Takeda-funded analysis finds, even with treatments available.
Federal HIV guidelines add Bixlenvo as a switch option, back statins for adults 40 to 75 and urge clinicians to challenge payer barriers to antiretroviral therapy (ART).
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Updated HIV treatment guidelines address payer barriers and add Bixlenvo
2
5 things you should know about the midterms and healthcare
3
What stands in the way of patients with atopic dermatitis getting prescription medication? Here are some possibilities
4
Narcolepsy type 1 drives 5-fold higher costs in first year after diagnosis
5